Atossa Therapeutics Stock Number Of Employees

YAG2 Stock  EUR 1.20  0.01  0.83%   
Atossa Therapeutics fundamentals help investors to digest information that contributes to Atossa Therapeutics' financial success or failures. It also enables traders to predict the movement of Atossa Stock. The fundamental analysis module provides a way to measure Atossa Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atossa Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Atossa Therapeutics Company Number Of Employees Analysis

Atossa Therapeutics' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Number of Employees

 = 

Full Time

+

Part Time

More About Number Of Employees | All Equity Analysis

Current Atossa Therapeutics Number Of Employees

    
  6  
Most of Atossa Therapeutics' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atossa Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Competition

Based on the recorded statements, Atossa Therapeutics is currently employing 6.0 people. This is 99.95% lower than that of the Healthcare sector and 98.88% lower than that of the Biotechnology industry. The number of employees for all Germany stocks is 99.97% higher than that of the company.

Atossa Number Of Employees Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atossa Therapeutics' direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atossa Therapeutics could also be used in its relative valuation, which is a method of valuing Atossa Therapeutics by comparing valuation metrics of similar companies.
Atossa Therapeutics is currently under evaluation in number of employees category among its peers.

Atossa Fundamentals

About Atossa Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Atossa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atossa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atossa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Atossa Stock

Atossa Therapeutics financial ratios help investors to determine whether Atossa Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Atossa with respect to the benefits of owning Atossa Therapeutics security.